Addex Therapeutics Ltd. — Form 6-K Summary
Filing date: October 8, 2026. The filing reports that Addex issued a press release on that date, furnished as Exhibit 99.1. The text provided does not include the press release itself or describe its subject.
Business context and reporting period
Addex Therapeutics Ltd. is a foreign private issuer headquartered in Geneva, Switzerland, and files annual reports on Form 20-F. This 6-K is a current report concerning an October 8, 2026 press release, not a financial-results report.
Financial performance and changes
The provided filing text contains no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period results or changes.
Outlook, risks, and other matters
No specific guidance, outlook, management commentary, contingencies, or unusual financial items are described in the provided text. The company refers investors to risk factors in its 2025 Form 20-F, filed May 15, 2026, and cautions that actual results may differ materially from forward-looking statements. Exhibit 99.1 is incorporated by reference into the specified Form F-3 and Form S-8 registration statements, subject to subsequent filings or reports.
Investor verification priorities
- Review Exhibit 99.1 to establish what the October 8, 2026 press release announced; its contents are not included in the supplied text.
- Consult the 2025 Form 20-F and other SEC filings for the company’s financial position and detailed risk factors.
- Check subsequent filings for updates or information that may supersede the incorporated material.